trial

Metabolic Signatures and Biomarkers in Schizophrenia

NCTId NCT00466310
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 71 (actual)
Sponsored by Duke University
Primary completion 2009-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
71 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2007-02
Primary completion
2009-01
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
AripiprazoleRisperidoneHealthy volunteers

Sponsors

Duke UniversityLead Sponsor
Bristol-MyersCollaborator

Investigators

1
Rima Kaddurah-Daouk, MDPrincipal Investigator

Sites

1 total
Butner, United States

Facts & assertions

4 sourced
Enrollment
71
Phase
PHASE1
Primary Completion Date
2009-01
Status
COMPLETED
relationships
The graph out of here
drug
Aripiprazole
drug
Risperidone
drug
Healthy volunteers
drug
lead_sponsor
Duke University
company
collaborator
Bristol-Myers
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Rima Kaddurah-Daouk, MD
person